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Background: It is unclear how depressive symptoms in patients with heart failure develop over time and
whether this trajectory of depressive symptoms is associated with hospital admission and prognosis.
Aim: To describe the time-course of depressive symptoms and determine the relationship with hospitalisation
and mortality.
Method: Data was analysed using 611 patients with completed CES-D questionnaires at baseline and at
18 months. Data on hospitalisation was collected 18 months after discharge and data on mortality was collect-
ed 18 and 36 months post-discharge.
Results: A total of 140 (61%) of the 229 patients with depressive symptoms at discharge had recovered from de-
pressive symptoms after 18 months whereas 71 (18%) of the 382 non-depressed developed depressive symp-
toms and 89 (39%) of the 229 depressed remained depressed. Patients with recently (i.e. during the last
18 months) developed depressive symptoms showed a signiﬁcantly higher risk for cardiovascular hospitalisation
(HR 1.7, 95% CI 1.1–2.6, P=.016). After 36 months, patients with developed depressive symptoms after discharge
were at a higher risk of all-causemortality (HR2.0, 95% CI 1.2–3.5, P=.012) and therewas a trend towards a higher
risk of all-cause mortality in patients with ongoing depressive symptoms (HR 1.7, 95% CI 0.98–3.1, P=.056).
Conclusion:A signiﬁcant proportion of patients with HF, whowere reported depressive symptoms at discharge re-
covered from depressive symptoms during the following 18 months. However, patients who remained having de-
pressive symptoms or patients who developed depressive symptoms had a worse prognosis.
© 2012 Elsevier Inc. All rights reserved.
Introduction
Heart failure (HF) is a clinical syndrome that is increasing in inci-
dence worldwide. It results in high morbidity and mortality, and a
lower ﬁve year survival rate than many common forms of cancer such
as breast and prostate cancer [1]. Major depression and depressive
symptoms are common in patients with HF and signiﬁcantly more fre-
quent compared to an age and gender matched population [2]. It is es-
timated that 16%–38 % of patients with HF have depressive symptoms,
depending on the type of assessment diagnostic instruments used [3].
The presence of depressive symptoms, even in the absence of a con-
ﬁrmed diagnosis of major depressive disorder, increases the risk of
non-compliance [4,5], delay in seeking hospital care [6], higher usage
of health care resources and clinical events [7,8]. In addition, the pres-
ence of depression may also affect the impact of disease management
programs, as these interventions may not be as effective in depressed
patients [9].
Despite these adverse outcomes of depression in HF patients, only
a few trials have been published that address treatment and the
results are inconclusive [10,11]. In the large scaled SADHART-CHF
study (n=469), treatment with selective serotonin re-uptake inhibi-
tor (SSRI) was not favourable compared to placebo regarding reduc-
tions in depressive symptoms as well as in long-term follow-up end
points [10]. In a small pilot study (n=36), however, SSRI improved
depressive symptoms and general health perceptions, compared
with placebo [11].
Others have shown that changes in depressive symptoms are
associated to poorer outcomes. In patients with HF (n=147) an in-
crease in Beck Depression Inventory score (BDI) from baseline to
1-year follow-up was associated with an increased number of cardio-
vascular hospitalisations and deaths over a median of 5 years follow-up
from baseline [12]. Blumenthal and colleagues, in their study of effects
of exercise training on depressive symptoms, had the same experience
and reported that a decrease in BDI score between baseline and
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3-month follow-up was associated with an increased number of
hospitalisations and deaths [13]. However these studies did not re-
port on the proportions of patients whose depression remitted, or
those that, stayed depressed or developed depression. From the
ENRICHD study (a study in post MI patients), it is known that a
large proportion of depressed patients remit spontaneously, without
any structured intervention [14]. The same experience has been
reported in HF patients [15,16]. In the study of Fulop and colleagues,
patients with depressive symptoms at 24 weeks (persistent or re-
cently developed) also used signiﬁcantly more health care resources
compared to those without depressive symptoms [15]. In the study
of Dekker and colleagues, patients with persistent or incident de-
pressive symptoms at 3 or 6 months had the worst health-related
quality of life [16]. With the exception of these two studies [15,16]
it is today unclear how depressive symptoms in HF patients develop
over time and how this trajectory of depressive symptoms is associ-
ated with hospital admission and prognosis. Such information could
help in the interpretation of the effect of depressive symptoms on
clinical events and might also guide optimal timing of assessment
for depressive symptoms in HF.
The purpose of this study was to describe the time-course of de-
pressive symptoms in patients with HF during 18 months following
hospitalisation due to HF and determine its relationship with the
hospital admission rate and mortality. A second purpose was to com-
pare the prognostic information of depressive symptoms assessed
18 months after hospital discharge.
Methods
Study design
Data was collected in the COACH (Coordinating study evaluating
Outcomes of Advising and Counselling in Heart failure) study and
additional long-term follow-up data was collected. COACH was a
multi-centre, randomised trial designed to compare basic and inten-
sive support to standard treatment in patients with HF. The method-
ology, main results and baseline depression data of the trial have been
published previously [17–19]. In summary, patients were recruited
during a period of 28 months from October 2002 to February 2005.
All patients had been admitted to hospital with symptoms of HF,
New York Heart Association (NYHA) functional classiﬁcation II–IV.
Patients were >18 years of age and had evidence of structural underly-
ing heart disease. Major exclusion criteria were: concurrent inclusion
in another study or in a HF clinic, inability to complete the question-
naires; any invasive procedure or cardiac surgery intervention within
the last 6 months or planned during the following 3 months; ongoing
evaluation for heart transplantation; and inability or unwillingness to
give informed consent. After written informed consent, patients were
randomised into three groups: care as usual and two intervention groups
(basic and intensive support). Patients completed questionnaires and
were interviewed by an independent interviewer not involved in the
care for these patients. The Central Ethics Committee approved the
study, including the 3-year extended follow-up, and the investigation
conformed to the principles outlined in the Declaration of Helsinki.
Measurements
Depressive symptoms
Depressive symptoms were assessed by The Centre for Epidemiolog-
ical Studies Depression Scale (CES-D). This questionnaire was adminis-
tered a few days before discharge from the hospital and 18 months
after hospitalisation. The CES-D is a 20-item self-report questionnaire
designed to measure depressive symptoms in the general population
and in themedically ill [20]. A total sum score is used (0–60),with higher
scores indicating more depressive symptoms. A cut-off point of 16,
which is generally used to deﬁne patients at risk of clinical depression
was used to distinguish between HF patients with depressive symptoms
(CES-D≥16) and patients without depressive symptoms (CES-Db16).
By using baseline and 18-month data, patients were classiﬁed into 4 cat-
egories of depressive symptoms: 1) ongoing: patients with depressive
symptoms at index hospitalisation and at the 18-month follow-up; 2)
remission: patients with depressive symptoms at index hospitalisation
but not at 18-month follow-up; 3) new episode: patients without de-
pressive symptoms at index hospitalisation but with depressive symp-
toms at 18-month follow-up and 4) non depressed: patients without
depressive symptoms at index hospitalisation and 18-month follow-up.
Hospitalisation and mortality
Data onhospitalisation andmortalitywas collected from the patient's
medical record and by interviews with the patient during follow-up. In
this study, data on hospitalisation was collected 18 months after dis-
charge whereas data on mortality was collected at 18 and 36 months
after discharge. Hospitalisation was deﬁned as an unplanned overnight
stay in a hospital due to any cause. Regarding the 18-month follow-up
period, reason for hospitalisation, cause of death and date of the event
were adjudicated by a central end-point committee. Concerning the
36-month (1095 days) follow-up, only data on mortality was collected










Fig. 1. Course of depressive symptoms in HF patients during the 18-month follow-up. (n=611).
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Demographic and clinical data
Demographic and clinical variables known from the literature, to
be potentially important prognostic factors in the relation between
the course of depressive symptoms and adverse events in HF patients
were identiﬁed. Demographic factors included age, sex, and living situa-
tion andwere assessed by patient interviewduring index hospitalisation.
Clinical factors included primary reason for HF, the presence of co-
morbidity (e.g. asthma/COPD, diabetes, rheumatoid arthritis, renal
disease, stroke and hypertension), disease severity (B-type Natriuretic
Peptide-BNP) and history of HF hospitalisation, which were collected
from medical records and by patient interview.
Statistical analysis
The prevalence of depressive symptoms was calculated at baseline
and 18 months after discharge. Bivariate analyses were conducted to
compare demographic and clinical characteristics at baseline among
the 4 depressive symptom status groups (ongoing depression, recovered
depression, new depressive episode, and persistent non-depressed).
Outcomes, days to ﬁrst hospitalisation and mortality were compared
among the different categories of depressive symptom status by
chi-square tests for categorical data and by non-parametric tests
(Kruskal–Wallis) for continuous variables. Multivariable propor-
tional hazard regression models were used to evaluate the indepen-
dent association between depressive symptom status and the risk of
hospital admissions and mortality. Firstly we evaluated the change
in CES-D score over the 18 months follow-up period (CES-D score
at 18 months minus baseline CES-D score). Secondly, to facilitate
communication and summarisation of ﬁndings we also evaluated the 4
depressive symptom status groups (ongoing, recovered, new episode,
non-depressed). Kaplan–Meier curve analyses were performed to inves-
tigate the association between depression symptom status groups and
hospitalisation after 18 months and mortality 36 months after hospital
discharge. The multivariate analyses were adjusted for demographics
age, sex, chronic obstructive pulmonary disease, diabetes, ischemic HF,
baseline BNP level, and history of history of HF hospitalisation because
of their known inﬂuence on outcome and/or because they differed signif-
icantly by depression status (Pb .05). In the continuous analysis we also
adjusted for baseline CES-D score. In the analysis of the risk of
hospitalisation, a previous history of HF hospitalisation (yes or no
format) was one or more events prior to inclusion in the study,
whereas in the 36 months mortality analysis. A previous history of HF
hospitalisation refers to one or more events during the 18-month
follow-period. In the present study data on all patients in the COACH
study was analysed as one rather than three intervention groups, since
the presence of depressive symptoms was equally distributed among
the intervention groups at baseline and the intervention was not associ-
ated with readmission or mortality. SPSS 18.0 (IBM, SPSS, Chicago, IL)
was used for statistical analyses.
Results
Study sample
A total of 1023 patients with HF were enrolled in the COACH study and 958 and 649
patients completed the CES-D at baseline and after 18 months respectively. Analyseswere
performed on the 611 patients with a complete CES-D score at baseline as well as at
18-month follow-up. The main reason for missing CES-D data at the 18-month
follow-up was mortality (n=271). Those who did not complete the CES-D at follow-up
(n=412) were signiﬁcantly older, had more comorbidity, and a higher mean baseline
CES-D score.
Prevalence and time-course of depressive symptoms
Of the 611 HF patients, 229 (38%) reported depressive symptoms (CES-D≥16) at
index hospitalisation. Eighteen months after discharge, 160 (26%) of the 611 patients
reported depressive symptoms. In total, 61% (n=140) of the 229 HF patients who
were depressed during the index hospitalisation remitted from depressive symptoms
(CES-Db16) whereas 39% (n=89) still had a CES-D score ≥16 (ongoing depressive
symptoms) at 18 months post-discharge. Out of the 382 patients without depressive
symptoms at index hospitalisation, 81% (n=311) remained without depressive symptoms
whereas 19% (n=71) had developed depressive symptoms at 18 months follow-up
(Fig. 1). Patients with ongoing depressive symptoms or with a new episode of depressive
symptoms were more likely to have diabetes, COPD and a history of previous HF
hospitalisations compared to those who recovered from depression. Patients who recov-
ered from depression had higher BNP levels at hospital discharge, but there was no differ-
ence in prescription of antidepressants (Table 1).
Outcomes
Association between the trajectory of depression and hospitalisation 18 months after
discharge
The multivariate proportional hazard regression analyses showed that an increase
in depression symptoms as indicated by a higher CES-D score (1 point CES-D change)
over an 18-month interval, after adjustments (i.e. age, sex, baseline CES-D score, COPD,
diabetes, ischemic HF, baseline BNP level and history of HF hospitalisation previous
inclusion in the study) was signiﬁcantly associated with a small increased risk of
hospitalisation because of cardiovascular reasons (HF included) (HR 1.02 CI 95%
1.01–1.04, P=.003) and of all-cause hospitalisation (HR 1.02 CI 95% 1.01–1.04, P=
.003) but not of hospitalisation due to HF (HR 1.02 CI 95% 0.99–1.04, P=.07). Patients
with depressive symptoms at 18 months (i.e. ongoing or recently developed) were
more often readmitted during the 18-month of follow-up compared to patients with-
out or who recovered from depressive symptoms (61% and 61% vs. 44% and 47% re-
spectively, Pb .01) (Table 2). More patients with ongoing or recently developed
depressive symptoms were hospitalized related to HF only, or for cardiovascular rea-
sons (HF included) (P=.03 and P=.01 respectively) (Table 2). However, in multivar-
iate proportional hazard regression analyses (adjusted for age, sex, BNP level, COPD,
diabetes, ischemicHF, history of HF hospitalisations), only patientswith recently developed
depressive symptoms showed a signiﬁcantly higher risk of all-cause hospitalisation (HR1.5,
95% CI 1.03–2.2, P=.035) and CV hospitalisation (HR 1.7, 95% CI 1.1–2.6, P=.016), but not
of HF hospitalisation (HR 1.4, 95% CI 0.8–2.7, P=.21).
Association between depression status, the trajectory of depression and all-cause mortality
36 months after discharge
Of the patients with depressive symptoms at the follow-up 18 months after discharge,
the follow-up analysis 18 months after that re-assessment (i.e. 36 months after hospital
discharge) showed that 26% of the depressed patients had died, compared to 15% among
non-depressed patients (Log rank P=.001; Fig. 2). The 18-month change in CES-D scores
after adjustments (i.e. age, sex, baseline CES-D score, COPD, diabetes, ischemic HF, baseline
BNP level and history of HF hospitalisation during the 18 months follow-up) was signiﬁ-
cantly associated with a higher 36-month mortality (HR 1.04 CI 95% 1.02–1.06, Pb .001).
Unadjusted Kaplan Meier curves showed signiﬁcant differences in all-cause mortality at
the 36-month follow-up regarding depressive symptom status (Log rank P=.008; Fig. 3).
A total of 25% of patients with ongoing depression and 28% of patients with recently devel-
oped depression had died and 15% and 16% of patients who remitted or were
non-depressed had died at the 36-month follow-up (Table 2). In the multivariate propor-
tional hazard regression analyses (i.e. age, sex, COPD, diabetes, ischemic HF, baseline BNP
level and previous HF readmission) patients with recently developed depressive symptoms
were at signiﬁcantly higher risk of all-cause mortality (HR 2.0, 95% CI 1.2–3.5, P=.012). In
patients with ongoing depression, therewas only a trend towards a higher risk for all-cause
mortality (HR 1.7, 95% CI 0.98–3.1, P=.056).
Discussion
To our knowledge, this is one of the ﬁrst studies to investigate the
time-course of depressive symptoms in HF patients and the relation-
ship with hospitalisation and mortality. It was found that 61% of pa-
tients with depressive symptoms had recovered 18 months after
hospitalisation, whereas 19% of those without depressive symptoms
had developed depressive symptoms. Increase in depressive symptoms
fromhospitalisation to 18 months follow-up provided prognostic infor-
mation. Patients with recently developed depressive symptomswere at
a particularly higher risk of both hospitalisation and mortality.
From initial assessment of depressive symptoms during hospital-
isation to re-assessment 18 months later, the occurrence of depressive
symptoms decreased from 38% to 26%. Almost the same ﬁgureswere de-
scribed in the study by Fulop and colleagues who described that depres-
sive symptoms in HF patients decreased from 36% at hospital to 26%
24 weeks post-discharge [15]. We found that 61% of patients who were
depressed during hospitalisation had remitted in 18 months without
signiﬁcant antidepressant treatment. A recent sub-analysis of data from
the SADHART-trial showed that 68% of those in the placebo group remit-
ted from depression after the 14 week study period [21]. The present
study, all patients received follow-up with different levels of intensity
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[18], either by nurses or cardiologists. In the SADHART-CHF study both
treatment and placebo groups were supported by nurses throughout
the study period [10]. The high rates of remissions in the present study
and in SADHART-CHF may therefore not be generalised to an ordinary
HF population. However, in the study by Fulop et al. in which HF patients
did not receive any speciﬁc structured follow-ups, 47% and 71% had
remitted from depressive symptoms 4 and 24 weeks post-discharge
[15]. High rates of remission was also reported in a recent study of the
trajectory of depressive symptoms inHF, inwhich 50% of the patients ex-
perienced improvements by 3 to 6 months [16].
One explanation for remission is that depression and HF to some
extent share the same somatic symptoms (i.e. fatigue, sleep distur-
bances and loss of appetite). Additionally, we found higher BNP levels
at discharge in those who had remitted from depressive symptoms at
follow-up. It is therefore plausible that some of the remitting patients
might have been falsely labelled as depressed. Another possible expla-
nation for the high hospitalisation rate is that depressive symptoms
during hospitalisationmay reﬂect a reactive depression. After discharge
a HF stabilisation and improvements in patients physical and emotional
status can be expected [22],whichmay inﬂuence remissionof depression.
Regression to themean could be another potential additional explanation
for the reduction in depressive symptoms.
The results of the present study also showed that a change in depres-
sive symptoms from discharge from hospital to 18-months follow-up
provided prognostic information. In particular it was those patients
who had developed depression who was at a signiﬁcantly higher risk
whereas those with ongoing depression were at borderline risk predic-
tive of a poorer outcome. Blumenthal and colleagues reported that in pa-
tientswhohad undergone coronary artery by-pass surgery (CABG) those
with a CES-D score≥16 at discharge and 6-months later, had an in-
creased mortality, whereas those with remitting or newly developed
depression had not [23]. However, the HR for the CABG patients with
newly developed depression was much the same as that for ongoing
Table 1



















Age, y 69±11 69±11 68±13 70±13 69±11 0.79
Female sex 38% 43% 49%3,4 34% 33% 0.004
















COPD 27% 45%2,3,4 25% 28% 23% b0.001
Diabetes 24% 27% 19% 35%2,4 23% 0.06
Ischemic aetiology 40% 35% 31% 45%2, 44%2 0.03
History of HF
hospitalisationsa
27% 34% 21% 30% 27% 0.21
Medication
ACE/ARB 85% 79%4 85% 82% 88% 0.10
Beta blocker 68% 63% 70% 65% 69% 0.65
Diuretics 96% 96% 94% 97% 96% 0.79
Anti depressants 6% 11%4 8% 7% 4% 0.09
Support
Care as usual 32% 37% 31% 31% 32% 0.78
Basic intervention 34% 33% 34% 34% 34%
Intensive intervention 34% 30% 35% 35% 34%
Note: ACE-I/ARB — angiotensin converting inhibitor/angiotensin receptor blockers; BNP — brain natriuretic peptide; COPD — chronic pulmonary disease; HF — heart failure; IQR —
inter quartile range:
1 ongoing depressive symptoms; 2 remission depressive symptoms; 3 new episode depressive symptoms; 4 no depressive symptoms.
a Hospitalisation due to heart failure previous inclusion in the study.
Table 2























HF hospitalisation 27% 15% 25% 16% 0.03
CV hospitalisation
(incl. HF)
43% 32% 49% 31% 0.01
All-cause
hospitalisation
61% 47% 61% 44% 0.01
All-cause mortality
3-year follow-up 25% 16% 28% 15% 0.01
Note: CV — cardiovascular; HF — heart failure.
Fig. 2. Unadjusted Kaplan Meier curve of depression symptoms status re-assessed
18 months after discharge and all-cause mortality after 18 months (i.e. three years
post-discharge).
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depression, and the lack of signiﬁcance may be explained the by a small
number of patients in the latter group (n=36). Another study by the
COACH study group had previously shown that baseline CES-D>24,
and not CES-D score of ≥16 was associated with poor outcomes [8].
This is in line with Blumenthal et al. who suggested that a baseline
score on the CES-D of ≥27, or a CES-D≥16 at baseline and 6 months,
may identify patients with clinical depression [23]. A sub-study of the
SADHART trial described that non-remission was more common in HF
patients who at baseline were assed to have severe depression, and that
those who did not remit had a worse prognosis [24]. This suggests that
mild depressive symptoms are not predictive for poor outcomes. HF pa-
tients screened to have depressive symptoms during a hospitalisation
compared to those found in outpatient care aremore likely to experience
remission from depressive symptoms 3 to 6 months post-discharge [16].
This and to avoid adverse medical side-effects onemay suggest no to ini-
tiate treatment of depression during hospitalisation for HF, but to wait at
least onemonth post-discharge, until patients have stabilised [15]. There-
fore patients with severe depression could have a follow-up visit to
re-evaluate depressive symptoms and a possible treatment strategy. In
our study, patients who developed depression after discharge from the
hospital were at the highest risk of re-hospitalisation or mortality.
These results conﬁrm other studies that describe that outpatients with
HF, who report a ongoing or worsening of depressive symptoms are at
higher risk for decline in health-related quality of life [16], physical func-
tioning [25], cardiovascular hospitalisations or death [12]. It was also
found that patients with ongoing depression had a borderline signiﬁcant
risk of death (HR 1.7, 95% CI 0.98–3.1, P=.056). Studies in non HF
populations have shown that almost one-third of patients with remitted
depression will have a recurrence of depression [26]. Assessing the psy-
chological status of patients regularly, instead of only once in an outpa-
tient setting or primary care setting, may therefore be an important
strategy to identify HF patients who remain chronically depressed or
who develop depression. However, before implementation of routine
screening of depressive symptoms into clinical practice, establishment
of treatment programs for approaching depressive symptoms in patients
with HF and other cardiac diseases are needed [27].
It is important to note that this study was not primarily designed
to follow the trajectory and describe the natural history of depression
in patients with HF. The time interval of 18 months and the fact that
there were only twomeasurement points of depression leads the pos-
sibility that patients with cyclic states such as those with several
remission and recurrence periods, may go undetected. The question-
naire CES-D is a valid and frequently used instrument; however, it is
limited by the fact that it cannot be used to diagnose depression. De-
spite that we controlled for several important variables such as base-
line BNP and history of HF hospitalisations, is it possible that the
associations between poor outcomes and newly developed depres-
sion could reﬂect worsening of HF. Future studies exploring the tra-
jectory of depression in HF patients should screen for depression
using both questionnaires and diagnostic tools suggestively four
times during at least one year. Today there is a lack of knowledge
about the trajectory of depression in HF patients and we therefore
think that this study, despite its limitations, is of interest.
In summary, this study found that 61% of the patients’ depres-
sive symptoms recovered spontaneously at 18 months following
hospitalisation for HF. Patients who had depressive symptoms18
months after discharge from hospital were found to have a worse prog-
nosis. Thosewith a recently developed depressionwere at a particularly
high risk of hospital readmission or death. Routine assessments of HF
patients in primary care or at outpatient clinics in order to indentify re-
cently developed or chronic depressionsmay increase quality of life and
decrease the risk for adverse outcomes in heart failure patients.
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